85 related articles for article (PubMed ID: 2536288)
1. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study.
Buccheri GF; Ferrigno D; Curcio A; Vola F; Rosso A
Cancer; 1989 Feb; 63(3):428-32. PubMed ID: 2536288
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer.
Buccheri G; Ferrigno D; Rosso A
Cancer; 1993 Sep; 72(5):1564-72. PubMed ID: 8394198
[TBL] [Abstract][Full Text] [Related]
3. A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG).
Buccheri G; Ferrigno D
Eur J Cancer; 1994; 30A(10):1424-31. PubMed ID: 7833096
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of platinum-based regimens in non-small cell lung cancer. A negative report from the Cuneo Lung Cancer Study Group.
Buccheri G; Ferrigno D
Lung Cancer; 1997 Aug; 18(1):57-70. PubMed ID: 9268948
[TBL] [Abstract][Full Text] [Related]
5. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial.
Morton RF; Jett JR; McGinnis WL; Earle JD; Therneau TM; Krook JE; Elliott TE; Mailliard JA; Nelimark RA; Maksymiuk AW
Ann Intern Med; 1991 Nov; 115(9):681-6. PubMed ID: 1656827
[TBL] [Abstract][Full Text] [Related]
6. A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer.
Krook JE; Jett JR; Fleming TR; Dalton RJ; Marschke RF; Cullinan SA; Windschitl HE; Everson LK; Brunk FS; Laurie JA
J Clin Oncol; 1985 Jun; 3(6):842-8. PubMed ID: 3839263
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B.
Chahinian AP; Propert KJ; Ware JH; Zimmer B; Perry MC; Hirsh V; Skarin A; Kopel S; Holland JF; Comis RL
J Clin Oncol; 1989 Aug; 7(8):993-1002. PubMed ID: 2547030
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with methotrexate, adriamycin, cyclophosphamide and CCNU (MACC) for nonsmall cell lung cancer. 4-year experience with 92 patients.
Buccheri G; Ferrigno D; Vola F; Curcio A
Oncology; 1989; 46(4):212-6. PubMed ID: 2544837
[TBL] [Abstract][Full Text] [Related]
9. Quality of Life Achieved by Carboplatin Plus Etoposide as Third-Line Chemotherapy Compared with Best Supportive Care in Non-Small Cell Lung Cancer Stage IIIB/IV.
Maneechawakajorn J; Hathaisanguan S
J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S175-81. PubMed ID: 27266233
[TBL] [Abstract][Full Text] [Related]
10. Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer.
Umsawasdi T; Valdivieso M; Booser DJ; Barkley HT; Ewer M; MacKay B; Dhingra HM; Murphy WK; Spitzer G; Chiuten DF
Cancer; 1989 Nov; 64(10):1995-2000. PubMed ID: 2553235
[TBL] [Abstract][Full Text] [Related]
11. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer.
Cellerino R; Tummarello D; Guidi F; Isidori P; Raspugli M; Biscottini B; Fatati G
J Clin Oncol; 1991 Aug; 9(8):1453-61. PubMed ID: 1649267
[TBL] [Abstract][Full Text] [Related]
14. MACC (methotrexate, doxorubicin, cyclophosphamide and lomustine) versus cis-platinum and etoposide in the treatment of advanced non-small cell lung cancer.
Buccheri G; Ferrigno D; Curcio A; Vola F; Mattalia E
Chemioterapia; 1986 Feb; 5(1):53-7. PubMed ID: 3955784
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
Rapp E; Pater JL; Willan A; Cormier Y; Murray N; Evans WK; Hodson DI; Clark DA; Feld R; Arnold AM
J Clin Oncol; 1988 Apr; 6(4):633-41. PubMed ID: 2833577
[TBL] [Abstract][Full Text] [Related]
16. [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
Han BH; Xiu QY; Wang HM; Shen J; Gu AQ; Luo Y; Bai CX; Guo SL; Liu WC; Zhuang ZX; Zhang Y; Zhao YZ; Jiang LY; Shi CL; Jin B; Zhou JY; Jin XQ
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):854-9. PubMed ID: 22335953
[TBL] [Abstract][Full Text] [Related]
17. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.
Nyman J; Friesland S; Hallqvist A; Seke M; Bergström S; Thaning L; Lödén B; Sederholm C; Wagenius G
Lung Cancer; 2009 Jul; 65(1):62-7. PubMed ID: 19081652
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
Scagliotti GV; Fossati R; Torri V; Crinò L; Giaccone G; Silvano G; Martelli M; Clerici M; Cognetti F; Tonato M;
J Natl Cancer Inst; 2003 Oct; 95(19):1453-61. PubMed ID: 14519751
[TBL] [Abstract][Full Text] [Related]
19. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer.
Brown J; Thorpe H; Napp V; Fairlamb DJ; Gower NH; Milroy R; Parmar MK; Rudd RM; Spiro SG; Stephens RJ; Waller D; West P; Peake MD
J Clin Oncol; 2005 Oct; 23(30):7417-27. PubMed ID: 16157935
[TBL] [Abstract][Full Text] [Related]
20. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
